Current molecular and clinical insights into uveal melanoma (Review)
- Authors:
- Matteo Fallico
- Giuseppina Raciti
- Antonio Longo
- Michele Reibaldi
- Vincenza Bonfiglio
- Andrea Russo
- Rosario Caltabiano
- Giuseppe Gattuso
- Luca Falzone
- Teresio Avitabile
-
Affiliations: Department of Ophthalmology, University of Catania, I‑95123 Catania, Italy, Department of Drug Sciences, Section of Biochemistry, University of Catania, I‑95125 Catania, Italy, Department of Surgical Sciences, Eye Clinic Section, University of Turin, I‑10122 Turin, Italy, Department of Experimental Biomedicine and Clinical Neuroscience, Ophthalmology Section, University of Palermo, I‑90127 Palermo, Italy, Department ‘G.F. Ingrassia’, Section of Anatomic Pathology, University of Catania, I‑95123 Catania, Italy, Department of Biomedical and Biotechnological Sciences, University of Catania, I‑95123 Catania, Italy, Epidemiology Unit, IRCCS Istituto Nazionale Tumori ‘Fondazione G. Pascale’, I‑80131 Naples, Italy - Published online on: February 18, 2021 https://doi.org/10.3892/ijo.2021.5190
- Article Number: 10
-
Copyright: © Fallico et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM and Chen VW: Incidence of noncutaneous melanomas in the U.S. Cancer. 103:1000–1007. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Krantz BA, Dave N, Komatsubara KM, Marr BP and Carvajal RD: Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 11:279–289. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Damato B: Progress in the management of patients with uveal melanoma. the 2012 Ashton Lecture. Eye (Lond). 26:1157–1172. 2012. View Article : Google Scholar | |
|
Singh AD, Turell ME and Topham AK: Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM and Paci E; EUROCARE Working Group: Incidence of uveal melanoma in Europe. Ophthalmology. 114:2309–2315. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kivelä T: The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Br J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Margo CE, Mulla Z and Billiris K: Incidence of surgically treated uveal melanoma by race and ethnicity. Ophthalmology. 105:1087–1090. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Kaliki S, Cohen MN, Shields PW, Furuta M and Shields JA: Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture. Eye (Lond). 29:1027–1035. 2015. View Article : Google Scholar | |
|
Hu DN, Yu GP, McCormick SA, Schneider S and Finger PT: Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 140:612.e1–612.e8. 2005. View Article : Google Scholar | |
|
Kaliki S and Shields CL: Uveal melanoma: Relatively rare but deadly cancer. Eye (Lond). 31:241–257. 2017. View Article : Google Scholar | |
|
Singh AD and Topham A: Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 110:956–961. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Andreoli MT, Mieler WF and Leiderman YI: Epidemiological trends in uveal melanoma. Br J Ophthalmol. 99:1550–1553. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng CY and Hsu WM: Incidence of eye cancer in Taiwan: An 18-year review. Eye (Lond). 18:152–158. 2004. View Article : Google Scholar | |
|
Liu YM, Li Y, Wei WB, Xu X and Jonas JB: Clinical characteristics of 582 patients with uveal melanoma in China. PLoS One. 10:e01445622015. View Article : Google Scholar : PubMed/NCBI | |
|
Sakamoto T, Sakamoto M, Yoshikawa H, Hata Y, Ishibashi T, Ohnishi Y and Inomata H: Histologic findings and prognosis of uveal malignant melanoma in Japanese patients. Am J Ophthalmol. 121:276–283. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Singh AD, Schoenfield LA, Bastian BC, Aziz HA, Marino MJ and Biscotti CV: Congenital uveal melanoma? Surv Ophthalmol. 61:59–64. 2016. View Article : Google Scholar | |
|
Shields CL, Kaliki S, Arepalli S, Atalay HT, Manjandavida FP, Pieretti G and Shields JA: Uveal melanoma in children and teenagers. Saudi J Ophthalmol. 27:197–201. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vajdic CM, Kricker A, Giblin M, McKenzie J, Aitken J, Giles GG and Armstrong BK: Incidence of ocular melanoma in Australia from 1990 to 1998. Int J Cancer. 105:117–122. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Weis E, Shah CP, Lajous M, Shields JA and Shields CL: The association between host susceptibility factors and uveal melanoma: A meta-analysis. Arch Ophthalmol. 124:54–60. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Gonder JR, Ezell PC, Shields JA and Augsburger JJ: Ocular melanocytosis: A study to determine the prevalence rate of ocular melanocytosis. Ophthalmology. 89:950–952. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Kaliki S, Livesey M, Walker B, Garoon R, Bucci M, Feinstein E, Pesch A, Gonzalez C, Lally SE, et al: Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis analysis of 7872 consecutive eyes. JAMA Ophthalmol. 131:993–1003. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Singh AD, De Potter P, Fijal BA, Shields CL, Shields JA and Elston RC: Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology. 105:195–198. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Hammer H, Oláh J and Tóth-Molnár E: Dysplastic nevi are a risk factor for uveal melanoma. Eur J Ophthalmol. 6:472–474. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Bataille V, Sasieni P, Cuzick J, Hungerford JL, Swerdlow A and Bishop JA: Risk of ocular melanoma in relation to cutaneous and iris naevi. Int J Cancer. 60:622–626. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Territo C, Shields CL, Shields JA, Augsburger JJ and Schroeder RP: Natural course of melanocytic tumors of the iris. Ophthalmology. 95:1251–1255. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Kaliki S, Hutchinson A, Nickerson S, Patel J, Kancherla S, Peshtani A, Nakhoda S, Kocher K, Kolbus E, et al: Iris nevus growth into melanoma: Analysis of 1611 consecutive eyes: The ABCDEF guide. Ophthalmology. 120:766–772. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu M and Shields CL: Choroidal nevus in the United States adult population racial disparities and associated factors in the national health and nutrition examination survey. Ophthalmology. 122:2071–2083. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Singh AD, Kalyani P and Topham A: Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 112:1784–1789. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Cater J, Shields JA, Singh AD, Santos MCM and Carvalho C: Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Arch Ophthalmol. 118:360–364. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Furuta M, Berman EL, Zahler JD, Hoberman DM, Dinh DH, Mashayekhi A and Shields JA: Choroidal nevus transformation into melanoma: Analysis of 2514 consecutive cases. Arch Ophthalmol. 127:981–987. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Carbone M, Yang H, Pass HI, Krausz T, Testa JR and Gaudino G: BAP1 and cancer. Nat Rev Cancer. 13:153–159. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C and Bowcock AM: Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 330:1410–1413. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Singh AD, Rennie IG, Seregard S, Giblin M and McKenzie J: Sunlight exposure and pathogenesis of uveal melanoma. Surv Ophthalmol. 49:419–428. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt-Pokrzywniak A, Jöckel KH, Bornfeld N, Sauerwein W and Stang A: Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma. A case-control study Ophthalmology. 116:340–348. 2009. | |
|
Shah CP, Weis E, Lajous M, Shields JA and Shields CL: Intermittent and chronic ultraviolet light exposure and uveal melanoma: A meta-analysis. Ophthalmology. 112:1599–1607. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Fernandes BF, Marshall JC and Burnier MN Jr: Blue light exposure and uveal melanoma. Ophthalmology. 113:1062.e1author reply 1062. 2006. View Article : Google Scholar | |
|
Ge YR, Tian N, Lu Y, Wu Y, Hu QR and Huang ZP: Occupational cooking and risk of uveal melanoma: A meta-analysis. Asian Pac J Cancer Prev. 13:4927–4930. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Damato EM and Damato BE: Detection and time to treatment of uveal melanoma in the United Kingdom: An evaluation of 2,384 patients. Ophthalmology. 119:1582–1589. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Kaliki S, Shah SU, Luo W, Furuta M and Shields JA: Iris melanoma: Features and prognosis in 317 children and adults. J AAPOS. 16:10–16. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Demirci H, Shields CL, Shields JA, Eagle RC Jr and Honavar SG: Diffuse iris melanoma: A report of 25 cases. Ophthalmology. 109:1553–1560. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Demirci H, Shields CL, Shields JA, Eagle RC Jr and Honavar S: Ring melanoma of the anterior chamber angle: A report of fourteen cases. Am J Ophthalmol. 132:336–342. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, et al: Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 127:989–998. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Manalac J, Das C, Ferguson K and Shields JA: Choroidal melanoma: Clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol. 25:177–185. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Henderson E and Margo CE: Iris melanoma. Arch Pathol Lab Med. 132:268–272. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Singh AD and Damato B: Iris melanoma. Clinical Ophthalmic Oncology: Uveal Tumors. Springer; Berlin: pp. 137–158. 2014, View Article : Google Scholar | |
|
Shields CL, Manquez ME, Ehya H, Mashayekhi A, Danzig CJ and Shields JA: Fine-Needle aspiration biopsy of iris tumors in 100 consecutive cases: Technique and complications. Ophthalmology. 113:2080–2086. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bianciotto C, Shields CL, Guzman JM, Romanelli-Gobbi M, Mazzuca D Jr, Green WR and Shields JA: Assessment of anterior segment tumors with ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases. Ophthalmology. 118:1297–1302. 2011.PubMed/NCBI | |
|
Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S and Pfeffer U: The biology of uveal melanoma. Cancer Metastasis Rev. 36:109–140. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ossoinig KC: Standardized echography: Basic principles, clinical applications, and results. Int Ophthalmol Clin. 19:127–210. 1979. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Kaliki S, Rojanaporn D, Ferenczy SR and Shields JA: Enhanced depth imaging optical coherence tomography of small choroidal melanoma: Comparison with choroidal nevus. Arch Ophthalmol. 130:850–856. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Augsburger JJ, Golden MI and Shields JA: Fluorescein angiography of choroidal malignant melanomas with retinal invasion. Retina. 4:232–241. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Shields JA and De Potter P: Patterns of indocyanine green videoangiography of choroidal tumours. Br J Ophthalmol. 79:237–245. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Shields JA, Mashayekhi A, Ra S and Shields CL: Pseudomelanomas of the posterior uveal tract: The 2006 Taylor R. Smith lecture Retina. 25:767–771. 2005. View Article : Google Scholar | |
|
Shields CL, Dalvin LA, Ancona-Lezama D, Yu MD, Di Nicola M, Williams BK Jr, Lucio-Alvarez JA, Ang SM, Maloney S, Welch RJ and Shields JA: Choroidal nevus imaging features in 3,806 cases and risk factors for transformation into Melanoma in 2,355 cases: The 2020 Taylor R. Smith and Victor T Curtin Lecture Retina. 39:1840–1851. 2019. | |
|
Accuracy of Diagnosis of Choroidal Melanomas in the Collaborative Ocular Melanoma Study: COMS Report No. 1. Arch Ophthalmol. 108:1268–1273. 1990. View Article : Google Scholar | |
|
Char DH and Miller T: Accuracy of presumed uveal melanoma diagnosis before alternative therapy. Br J Ophthalmol. 79:692–696. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Shields JA, Shields CL, Ehya H, Eagle RC Jr and De Potter P: Fine-needle aspiration biopsy of suspected intraocular tumors. Int Ophthalmol Clin. 33:77–82. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Frizziero L, Midena E, Trainiti S, Londei D, Bonaldi L, Bini S and Parrozzani R: Uveal melanoma biopsy: A review. Cancers (Basel). 11:10752019. View Article : Google Scholar | |
|
Kivelä T, Simpson RE and Grossniklaus HE: Uveal melanoma. AJCC Cancer Staging Manual. 8th edition. Springer; New York, NY: 2016 | |
|
Edge S, Byrd D, Compton C, Fritz AG, Greene F and Trotti A: AJCC Cancer Staging Handbook. The AJCC Cancer Staging Manual. Springer-Verlag; New York, NY: 2010 | |
|
Hicks C, Foss AJ and Hungerford JL: Predictive power of screening tests for metastasis in uveal melanoma. Eye (Lond). 12:945–948. 1998. View Article : Google Scholar | |
|
Weis E, Salopek TG, McKinnon JG, Larocque MP, Temple-Oberle C, Cheng T, McWhae J, Sloboda R and Shea-Budgell M: Management of uveal melanoma: A consensus-based provincial clinical practice guideline. Curr Oncol. 23:e57–e64. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH and Chapman PB: Variates of survival in metastatic uveal melanoma. J Clin Oncol. 23:8076–8080. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, et al: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 123:1639–1643. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kivelä T: Iris melanomas in children. Arch Ophthalmol. 119:925–926. 2001.PubMed/NCBI | |
|
Kaliki S, Shields CL, Mashayekhi A, Ganesh A, Furuta M and Shields JA: Influence of age on prognosis of young patients with uveal melanoma: A matched retrospective cohort study. Eur J Ophthalmol. 23:208–216. 2013. View Article : Google Scholar | |
|
Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD and Smith A: Iris melanoma: Risk factors for metastasis in 169 consecutive patients. Ophthalmology. 108:172–178. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kujala E, Mäkitie T and Kivelä T: Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 44:4651–4659. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Kaliki S, Furuta M, Mashayekhi A and Shields JA: Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 32:1363–1372. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zloto O, Pe'er J and Frenkel S: Gender differences in clinical presentation and prognosis of uveal melanoma. Invest Ophthalmol Vis Sci. 54:652–656. 2013. View Article : Google Scholar | |
|
Hawkins BS; Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 138:936–951. 2004. View Article : Google Scholar | |
|
Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 124:1684–1693. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Diener-West M, Hawkins BS, Markowitz JA and Schachat AP: A review of mortality from choroidal melanoma: II. A Meta-Analysis of 5-Year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 110:245–250. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C and Shields JA: American Joint Committee on cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. Ophthalmology. 120:2066–2071. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Gragoudas ES and Egan KM: Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol. 118:1066–1070. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Kaliki S, Shields CL and Shields JA: Uveal melanoma: Estimating prognosis. Indian J Ophthalmol. 63:93–102. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pach JM, Robertson DM, Taney BS, Martin JA, Campbell RJ and O'Brien PC: Prognostic factors in choroidal and ciliary body melanomas with extrascleral extension. Am J Ophthalmol. 101:325–331. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
McLean MJ, Foster WD and Zimmerman LE: Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 95:48–58. 1977. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Jamal RT, Mäkitie T and Kivelä T: Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest Ophthalmol Vis Sci. 44:2381–2389. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH and Becher R: Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 347:1222–1225. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Kilic E, Naus NC, Van Gils W, Klaver CC, van Til ME, Verbiest MM, Stijnen T, Mooy CM, Paridaens D, Beverloo HB, et al: Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 46:2253–2257. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I and Field JK: Monosomy 3 in uveal melanoma: Correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci. 44:1008–1011. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ehlers JP, Worley L, Onken MD and Harbour JW: Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res. 14:115–122. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Aalto Y, Eriksson L, Seregard S, Larsson O and Knuutila S: Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 42:313–317. 2001.PubMed/NCBI | |
|
Onken MD, Worley LA, Ehlers JP and Harbour JW: Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 64:7205–7209. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, et al: Collaborative ocular oncology group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 119:1596–1603. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Harbour JW and Chen R: The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLoS Curr. April 9–2013.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
|
Field MG and Harbour JW: Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 25:234–239. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Eskelin S, Pyrhönen S, Summanen P, Hahka-Kemppinen M and Kivelä T: Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology. 107:1443–1449. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Natarajan S: Ocular oncology-a multidisciplinary specialty. Indian J Ophthalmol. 63:912015. View Article : Google Scholar | |
|
Rantala ES, Hernberg M and Kivelä TT: Overall survival after treatment for metastatic uveal melanoma: A systematic review and meta-analysis. Melanoma Res. 29:561–568. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Brewington BY, Shao YF, Davidorf FH and Cebulla CM: Brachytherapy for patients with uveal melanoma: Historical perspectives and future treatment directions. Clin Ophthalmol. 12:925–934. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rospond-Kubiak I and Damato B: The surgical approach to the management of anterior uveal melanomas. Eye (Lond). 28:741–747. 2014. View Article : Google Scholar | |
|
Jonas JB, Groh MJ, Rummelt V and Naumann GOH: Rhegmatogenous retinal detachment after block excision of epithelial implantation cysts and tumors of the anterior uvea. Ophthalmology. 106:1942–1946. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Nelson F, Stine GH and Danielson RW: Malignant melanoma of iris and ciliary body. Am J Ophthalmol. 29:13101946.PubMed/NCBI | |
|
Damato B, Kacperek A, Chopra M, Sheen MA, Campbell IR and Errington RD: Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol Phys. 63:109–115. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Finger PT: Plaque radiation therapy for malignant melanoma of the iris and ciliary body. Am J Ophthalmol. 132:328–335. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Naseripour M, Shields JA, Freire J and Cater J: Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: Tumor control and ocular complications. Am J Ophthalmol. 135:648–656. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lloyd JP and Ellis F: Melanoma of iris treated by radiation therapy. Br J Ophthalmol. 39:507–509. 1955. View Article : Google Scholar : PubMed/NCBI | |
|
Konstantinidis L, Roberts D, Errington RD, Kacperek A and Damato B: Whole anterior segment proton beam radiotherapy for diffuse iris melanoma. Br J Ophthalmol. 97:471–474. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Finger PT, Tomar AS and Chin KJ: Palladium-103 plaque therapy for multifocal iris melanoma: Radiation of the entire anterior segment of the eye. Eur J Ophthalmol. 1120672120914235:2020.Epub ahead of print. | |
|
Rundle P, Singh AD and Rennie I: Proton beam therapy for iris melanoma: A review of 15 cases. Eye (Lond). 21:79–82. 2007. View Article : Google Scholar | |
|
Rahmi A, Mammar H, Thariat J, Angellier G, Herault J, Chauvel P, Kodjikian L, Denis P and Grange JD: Proton beam therapy for presumed and confirmed iris melanomas: A review of 36 cases. Graefes Arch Clin Exp Ophthalmol. 252:1515–1521. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Shah SU, Bianciotto CG, Emrich J, Komarnicky L and Shields JA: Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: Impact of melanoma-related glaucoma on outcomes. Ophthalmology. 120:55–61. 2013. View Article : Google Scholar | |
|
American Brachytherapy Society-Ophthalmic Oncology Task Force. Electronic address: paulfinger@eyecancer.com; ABS-OOTF Committee: The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 13:1–14. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dogrusöz M, Jager MJ and Damato B: Uveal melanoma treatment and prognostication. Asia Pac J Ophthalmol (Phila). 6:186–196. 2017. | |
|
Honavar SG: Is collaborative ocular melanoma study (COMS) still relevant? Indian J Ophthalmol. 66:1385–1387. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Damato B: Legacy of the collaborative ocular melanoma study. Arch Ophthalmol. 125:966–968. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmerman LE, McLean IW and Foster WD: Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells? Br J Ophthalmol. 62:420–425. 1978. View Article : Google Scholar : PubMed/NCBI | |
|
Hawkins BS: Collaborative Ocular Melanoma Study randomized trial of I-125 brachytherapy. Clin Trials. 8:661–673. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Finger PT, Chin KJ and Duvall G; Palladium-103 for Choroidal Melanoma Study Group: Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 116:790–6. 796.e12009. View Article : Google Scholar : PubMed/NCBI | |
|
Verma V and Mehta MP: Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radiol). 28:e17–e27. 2016. View Article : Google Scholar | |
|
Gragoudas ES: Proton beam irradiation of uveal melanomas: The first 30 years. The weisenfeld lecture. Invest Ophthalmol Vis Sci. 47:4666–4673. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yang J, Manson DK, Marr BP and Carvajal RD: Treatment of uveal melanoma: Where are we now? Ther Adv Med Oncol. 10:17588340187571752018. View Article : Google Scholar : PubMed/NCBI | |
|
Damato B, Kacperek A, Errington D and Heimann H: Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol. 27:151–157. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Papakostas TD, Lane AM, Morrison M, Gragoudas ES and Kim IK: Long-term outcomes after proton beam irradiation in patients with large choroidal melanomas. JAMA Ophthalmol. 135:1191–1196. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dunavoelgyi R, Dieckmann K, Gleiss A, Sacu S, Kircher K, Georgopoulos M, Georg D, Zehetmayer M and Poetter R: Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997-2007. Int J Radiat Oncol Biol Phys. 81:199–205. 2011. View Article : Google Scholar | |
|
Gragoudas ES, Li W, Lane AM, Munzenrider J and Egan KM: Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology. 106:1571–1578. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Shields JA and Shields CL: Management of posterior uveal melanoma: Past, present, and Future: The 2014 Charles L. schepens lecture. Ophthalmology. 122:414–428. 2015. View Article : Google Scholar | |
|
Damato B and Lecuona K: Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: An audit of 1632 patients. Ophthalmology. 111:977–983. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Shields JA, Shields CL, Shah P and Sivalingam V: Partial lamellar sclerouvectomy for ciliary body and choroidal tumors. Ophthalmology. 98:971–983. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Peyman GA and Gremillion CM: Eye wall resection in the management of uveal neoplasms. Jpn J Ophthalmol. 33:458–471. 1989.PubMed/NCBI | |
|
Damato BE, Paul J and Foulds WS: Predictive factors of visual outcome after local resection of choroidal melanoma. Br J Ophthalmol. 77:616–623. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Foulds WS, Damato BE and Burton RL: Local resection versus enucleation in the management of choroidal melanoma. Eye (Lond). 1(Pt 6): 676–679. 1987. View Article : Google Scholar | |
|
Damato BE, Paul J and Foulds WS: Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol. 80:102–108. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Caminal JM, Padrón-Pérez N, Arias L, Masuet-Aumatell C, Gutiérrez C, Piulats JM, Pera J, Català J, Rubio MJ and Arruga J: Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma. Eye (Lond). 30:833–842. 2016. View Article : Google Scholar | |
|
Konstantinidis L, Groenewald C, Coupland SE and Damato B: Long-term outcome of primary endoresection of choroidal melanoma. Br J Ophthalmol. 98:82–85. 2014. View Article : Google Scholar | |
|
Biewald E, Lautner H, Gök M, Horstmann GA, Sauerwein W, Flühs D and Bornfeld N: Endoresection of large uveal melanomas: Clinical results in a consecutive series of 200 cases. Br J Ophthalmol. 101:204–208. 2017. View Article : Google Scholar | |
|
Süsskind D, Dürr C, Paulsen F, Kaulich T and Bartz-Schmidt KU: Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients-the Tuebingen experience. Acta Ophthalmol. 95:e727–e733. 2017. View Article : Google Scholar | |
|
Mashayekhi A, Shields CL, Rishi P, Atalay HT, Pellegrini M, McLaughlin JP, Patrick KA, Morton SJ, Remmer MH, Parendo A, et al: Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: Importance of risk factors in tumor control. Ophthalmology. 122:600–609. 2015. View Article : Google Scholar | |
|
Shields CL, Shields JA, Perez N, Singh AD and Cater J: Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: Outcomes and limitations. Ophthalmology. 109:225–234. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Harbour JW, Meredith TA, Thompson PA and Gordon ME: Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. Ophthalmology. 110:2207–2214; discussion 2215. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yarovoy AA, Magaramov DA and Bulgakova ES: The comparison of ruthenium brachytherapy and simultaneous transpupillary thermotherapy of choroidal melanoma with brachytherapy alone. Brachytherapy. 11:224–229. 2012. View Article : Google Scholar | |
|
Marinkovic M, Horeweg N, Fiocco M, Peters FP, Sommers LW, Laman MS, Bleeker JC, Ketelaars M, Luyten GP and Creutzberg CL: Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome. Eur J Cancer. 68:106–113. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, Dendale R, Delacroix S, Nauraye C, Estève M, Plancher C and Asselain B: Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: A randomized study of 151 patients. Ophthalmic Res. 38:255–260. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bellerive C, Aziz HA, Bena J, Wilkinson A, Suh JH, Plesec T and Singh AD: Local failure after episcleral brachytherapy for posterior uveal melanoma: Patterns, risk factors, and management. Am J Ophthalmol. 177:9–16. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cerman E and Çekiç O: Clinical use of photodynamic therapy in ocular tumors. Surv Ophthalmol. 60:557–574. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Turkoglu EB, Pointdujour-Lim R, Mashayekhi A and Shields CL: Photodynamic therapy as primary treatment for small choroidal melanoma. Retina. 39:1319–1325. 2019. View Article : Google Scholar | |
|
Liggett PE, Lavaque AJ, Chaudhry NA, Jablon EP and Quiroz-Mercado H: Preliminary results of combined simultaneous transpupillary thermotherapy and ICG-based photodynamic therapy for choroidal melanoma. Ophthalmic Surg Lasers Imaging. 36:463–470. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rose AM, Cowen S, Jayasena CN, Verity DH and Rose GE: Presentation, treatment, and prognosis of secondary melanoma within the orbit. Front Oncol. 7:1252017. View Article : Google Scholar : PubMed/NCBI | |
|
Finger PT and Chin KJ: Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: Secondary to plaque radiotherapy. Int J Radiat Oncol Biol Phys. 82:789–798. 2012. View Article : Google Scholar | |
|
Nagendran ST and Finger PT: Anti-VEGF intravitreal bevacizumab for radiation-associated neovascular glaucoma. Ophthalmic Surg Lasers Imaging Retin. 46:201–207. 2015. View Article : Google Scholar | |
|
Fallico M, Chronopoulos A, Schutz JS and Reibaldi M: Treatment of radiation maculopathy and radiation-induced macular edema: A systematic review. Surv Ophthalmol. Sep 10–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
|
Fallico M, Reibaldi M, Avitabile T, Longo A, Bonfiglio V, Chronopoulos A, Caltabiano R, Spatola C and Russo A: Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma. Graefes Arch Clin Exp Ophthalmol. 257:1547–1554. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gomez D, Wetherill C, Cheong J, Jones L, Marshall E, Damato B, Coupland SE, Ghaneh P, Poston GJ, Malik HZ and Fenwick SW: The Liverpool uveal melanoma liver metastases pathway: Outcome following liver resection. J Surg Oncol. 109:542–547. 2014. View Article : Google Scholar | |
|
Davanzo JM, Binkley EM, Bena JF and Singh AD: Risk-stratified systemic surveillance in uveal melanoma. Br J Ophthalmol. 103:1868–1871. 2019.PubMed/NCBI | |
|
Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH and Nathan PD: Metastatic disease from uveal melanoma: Treatment options and future prospects. Br J Ophthalmol. 101:38–44. 2017. View Article : Google Scholar : | |
|
Ralli M, Botticelli A, Visconti IC, Angeletti D, Fiore M, Marchetti P, Lambiase A, de Vincentiis M and Greco A: Immunotherapy in the treatment of metastatic melanoma: Current knowledge and future directions. J Immunol Res. 2020:92356382020. View Article : Google Scholar : PubMed/NCBI | |
|
Basile MS, Mazzon E, Russo A, Mammana S, Longo A, Bonfiglio V, Fallico M, Caltabiano R, Fagone P, Nicoletti F, et al: Differential modulation and prognostic values of immune-escape genes in uveal melanoma. PLoS One. 14:e02102762019. View Article : Google Scholar : PubMed/NCBI | |
|
Basile MS, Mazzon E, Fagone P, Longo A, Russo A, Fallico M, Bonfiglio V, Nicoletti F, Avitabile T and Reibaldi M: Immunobiology of uveal melanoma: State of the art and therapeutic targets. Front Oncol. 9:11452019. View Article : Google Scholar : PubMed/NCBI | |
|
Schadendorf D, Ascierto PA, Haanen JBAG, Espinosa E, Demidov LV, Garbe C, Lorigan P, Gogas H, Hoeller C, Guren TK, et al: Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). J Clin Oncol. 35(Suppl 15): S95242017. View Article : Google Scholar | |
|
Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, et al: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: A multicenter, retrospective study. J Immunother Cancer. 8:e0003312020. View Article : Google Scholar : PubMed/NCBI | |
|
Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC and Corless CL: Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 63:5761–5766. 2003.PubMed/NCBI | |
|
Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, et al: Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial. JAMA. 311:2397–2405. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, et al: Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 36:1232–1239. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, et al: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial. Lancet Oncol. 13:782–789. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shoushtari AN, Kudchadkar RR, Panageas K, Murthy RK, Jung M, Shah R, O'Donnell B, Khawaja TT, Shames Y, Prempeh-Keteku NA, et al: A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma. J Clin Oncol. 34(Suppl 15): S95112016. View Article : Google Scholar | |
|
Piperno-Neumann S, Kapiteijn E, Larkin JM, Carvajal RD, Luke JJ, Roozen HS, Zoubir M, Yang L, Choudhury S, Yerramilli-Rao P, et al: Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma. J Clin Oncol. 32(Suppl 15): 90302014. View Article : Google Scholar | |
|
Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ and Sato T: A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 22:440–446. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Valsecchi ME, Orloff M, Sato R, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ and Sato T: Adjuvant sunitinib in high-risk patients with uveal melanoma: Comparison with institutional controls. Ophthalmology. 125:210–217. 2018. View Article : Google Scholar | |
|
Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, et al: Randomized Phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201). Clin Cancer Res. 26:804–811. 2020. View Article : Google Scholar : | |
|
Scheulen ME, Kaempgen E, Keilholz U, Heinzerling L, Ochsenreither S, Abendroth A, Hilger RA, Grubert M, Wetter A, Guberina N, et al: STREAM: A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (S) treatment of chemonaïve patients (pts) with metastatic uveal melanoma (MUM). J Clin Oncol. 35:9511. 2017. View Article : Google Scholar | |
|
Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, et al: Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: An international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 30:1370–1380. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rowcroft A, Loveday BPT, Thomson BNJ, Banting S and Knowles B: Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 22:497–505. 2020. View Article : Google Scholar | |
|
Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, et al: Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): A multicentric randomized trial. Ann Oncol. 25:742–746. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vogl TJ, Koch SA, Lotz G, Gebauer B, Willinek W, Engelke C, Brüning R, Zeile M, Wacker F, Vogel A, et al: Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: Patient outcome and safety in a multi-centre study. Cardiovasc Intervent Radiol. 40:864–872. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gonsalves CF, Eschelman DJ, Adamo RD, Anne PR, Orloff MM, Terai M, Hage AN, Yi M, Chervoneva I and Sato T: A prospective Phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology. 293:223–231. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma A, Stei MM, Fröhlich H, Holz FG, Loeffler KU and Herwig-Carl MC: Genetic and epigenetic insights into uveal melanoma. Clin Genet. 93:952–961. 2018. View Article : Google Scholar | |
|
Lobo J, Pinto C, Freitas M, Pinheiro M, Vizcaino R, Oliva E, Teixeira MR, Jerónimo C and Bartosch C: Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: Consequence or coincidence? Virchows Arch. 470:347–352. 2017. View Article : Google Scholar | |
|
Rai K, Pilarski R, Cebulla CM and Abdel-Rahman MH: Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 89:285–294. 2016. View Article : Google Scholar | |
|
Larribère L and Utikal J: Update on GNA alterations in cancer: Implications for uveal melanoma treatment. Cancers (Basel). 12:15242020. View Article : Google Scholar | |
|
Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, Candido S and Libra M: Cutaneous melanoma: From pathogenesis to therapy (Review). Int J Oncol. 52:1071–1080. 2018.PubMed/NCBI | |
|
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al: Mutations in GNA11 in Uveal Melanoma. N Engl J Med. 363:2191–2199. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM and Harbour JW: Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 49:5230–5234. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM and Harbour JW: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 18:408–416. 2012. View Article : Google Scholar : | |
|
Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P and Davidorf FH: Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 48:856–859. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Levinzon L, Madigan M, Nguyen V, Hasic E, Conway M and Cherepanoff S: Tumour expression of histone deacetylases in uveal melanoma. Ocul Oncol Pathol. 5:153–161. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fabbri M and Calin GA: Epigenetics and miRNAs in human cancer. Adv Genet. 70:87–99. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cedar H and Bergman Y: Linking DNA methylation and histone modification: Patterns and paradigms. Nat Rev Genet. 10:295–304. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W and Xu J: DNA methyltransferases and their roles in tumorigenesis. Biomark Res. 5:12017. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Zhang J, Huang S and He X: Genome-wide analysis reveals that exon methylation facilitates its selective usage in the human transcriptome. Brief Bioinform. 19:754–764. 2018. View Article : Google Scholar | |
|
Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Falzone L, Salemi R, Travali S, Scalisi A, McCubrey JA, Candido S and Libra M: MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. Aging (Albany NY). 8:933–944. 2016. View Article : Google Scholar | |
|
Zhao Y, Sun H and Wang H: Long noncoding RNAs in DNA methylation: New players stepping into the old game. Cell Biosci. 6:452016. View Article : Google Scholar : PubMed/NCBI | |
|
Shayevitch R, Askayo D, Keydar I and Ast G: The importance of DNA methylation of exons on alternative splicing. RNA. 24:1351–1362. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ehrlich M and Lacey M: DNA methylation and differentiation: Silencing, upregulation and modulation of gene expression. Epigenomics. 5:553–568. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, Kuznetsov J, Bowcock AM, Kurtenbach S and Harbour JW: Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and 2 uveal melanomas. Oncotarget. 7:59209–59219. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Venza M, Visalli M, Catalano T, Beninati C, Teti D and Venza I: DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients. Hum Pathol. 60:137–146. 2017. View Article : Google Scholar | |
|
Merhavi E, Cohen Y, Avraham BC, Frenkel S, Chowers I, Pe'er J and Goldenberg-Cohen N: Promoter methylation status of multiple genes in uveal melanoma. Invest Ophthalmol Vis Sci. 48:4403–4406. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Moulin AP, Clément G, Bosman FT, Zografos L and Benhattar J: Methylation of CpG island promoters in uveal melanoma. Br J Ophthalmol. 92:281–285. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Maat W, Van Der Velden PA, Out-Luiting C, Plug M, Dirks-Mulder A, Jager MJ and Gruis NA: Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci. 48:486–490. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Maat W, Beiboer SH, Jager MJ, Luyten GP, Gruis NA and Van Der Velden PA: Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma. Invest Ophthalmol Vis Sci. 49:1291–1298. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Van der Velden PA, Zuidervaart W, Hurks MH, Pavey S, Ksander BR, Krijgsman E, Frants RR, Tensen CP, Willemze R, Jager MJ and Gruis NA: Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer. 106:472–479. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Neumann LC, Weinhäusel A, Thomas S, Horsthemke B, Lohmann DR and Zeschnigk M: EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation. BMC Cancer. 11:3802011. View Article : Google Scholar : PubMed/NCBI | |
|
Venza M, Visalli M, Catalano T, Fortunato C, Oteri R, Teti D and Venza I: Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma. Biochem Biophys Res Commun. 441:743–750. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Field MG, Kuznetsov JN, Bussies PL, Cai LZ, Alawa KA, Decatur CL, Kurtenbach S and Harbour JW: BAP1 loss is associated with DNA methylomic repatterning in highly aggressive class 2 uveal melanomas. Clin Cancer Res. 25:5663–5673. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Falzone L, Romano GL, Salemi R, Bucolo C, Tomasello B, Lupo G, Anfuso CD, Spandidos DA, Libra M and Candido S: Prognostic significance of deregulated microRNAs in uveal melanomas. Mol Med Rep. 19:2599–2610. 2019.PubMed/NCBI | |
|
Beyer S, Fleming J, Meng W, Singh R, Haque SJ and Chakravarti A: The Role of miRNAs in angiogenesis, invasion and metabolism and their therapeutic implications in gliomas. Cancers (Basel). 9:852017. View Article : Google Scholar | |
|
Napoli S, Scuderi C, Gattuso G, Bella VD, Candido S, Basile MS, Libra M and Falzone L: Functional roles of matrix metalloproteinases and their inhibitors in melanoma. Cells. 9:11512020. View Article : Google Scholar : | |
|
Filetti V, Falzone L, Rapisarda V, Caltabiano R, Eleonora Graziano AC, Ledda C and Loreto C: Modulation of microRNA expression levels after naturally occurring asbestiform fibers exposure as a diagnostic biomarker of mesothelial neoplastic transformation. Ecotoxicol Environ Saf. 198:1106402020. View Article : Google Scholar : PubMed/NCBI | |
|
Falzone L, Grimaldi M, Celentano E, Augustin LSA and Libra M: Identification of modulated MicroRNAs associated with breast cancer, diet, and physical activity. Cancers (Basel). 12:25552020. View Article : Google Scholar | |
|
Polo A, Crispo A, Cerino P, Falzone L, Candido S, Giudice A, De Petro G, Ciliberto G, Montella M, Budillon A and Costantini S: Environment and bladder cancer: Molecular analysis by interaction networks. Oncotarget. 8:65240–65252. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Crimi S, Falzone L, Gattuso G, Grillo CM, Candido S, Bianchi A and Libra M: Droplet Digital PCR analysis of liquid biopsy samples unveils the diagnostic role of hsa-miR-133a-3p and hsa-miR-375-3p in oral cancer. Biology (Basel). 9:3792020. | |
|
Venza M, Dell'Aversana C, Visalli M, Altucci L, Teti D and Venza I: Identification of microRNA expression patterns in cutaneous and uveal melanoma cell lines. Tumori. 100:e4–e7. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Radhakrishnan A, Badhrinarayanan N, Biswas J and Krishnakumar S: Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Mol Vis. 15:2146–2154. 2009.PubMed/NCBI | |
|
Larsen AC, Holst L, Kaczkowski B, Andersen MT, Manfé V, Siersma VD, Kolko M, Kiilgaard JF, Winther O, Prause JU, et al: MicroRNA expression analysis and Multiplex ligation-dependent probe amplification in metastatic and non-metastatic uveal melanoma. Acta Ophthalmol. 92:541–549. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Worley LA, Long MD, Onken MD and Harbour JW: Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 18:184–190. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Wang J, Shen H, Lu J, Li C, Hu DN, Dong XD, Yan D and Tu L: Epigenetics, microRNAs, and carcinogenesis: Functional role of microRNA-137 in uveal melanoma. Invest Ophthalmol Vis Sci. 52:1193–1199. 2011. View Article : Google Scholar | |
|
Li Y, Huang Q, Shi X, Jin X, Shen L, Xu X and Wei W: MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate-1. Chin Med J (Engl). 127:1410–1416. 2014. | |
|
Eedunuri VK, Rajapakshe K, Fiskus W, Geng C, Chew SA, Foley C, Shah SS, Shou J, Mohamed JS, Coarfa C, et al: miR-137 targets p160 steroid receptor coactivators SRC1, SRC2, and SRC3 and inhibits cell proliferation. Mol Endocrinol. 29:1170–1183. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Venza M, Visalli M, Beninati C, Benfatto S, Teti D and Venza I: miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells. Int Immunopharmacol. 40:235–243. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sun L, Bian G, Meng Z, Dang G, Shi D and Mi S: MiR-144 inhibits uveal melanoma cell proliferation and invasion by regulating c-Met expression. PLoS One. 10:e01244282015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, He X, Li F, Pan H, Huang X, Wen X, Zhang H, Li B, Ge S, Xu X, et al: The miR-181 family promotes cell cycle by targeting CTDSPL, a phosphatase-like tumor suppressor in uveal melanoma. J Exp Clin Cancer Res. 37:152018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Luo Y, Guan W and Zhao H: Role of mir-23a/zeb1 negative feedback loop in regulating epithelial-mesenchymal transition and tumorigenicity of intraocular tumors. Oncol Lett. 16:2462–2470. 2018.PubMed/NCBI | |
|
Wang YC, Yang X, Wei WB and Xu XL: Role of microRNA-21 in uveal melanoma cell invasion and metastasis by regulating p53 and its downstream protein. Int J Ophthalmol. 11:1258–1268. 2018.PubMed/NCBI | |
|
Li J, Liu X, Li C and Wang W: miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma. J Cell Biochem. 120:12412–12421. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sun L, Wang Q, Gao X, Shi D, Mi S and Han Q: MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma. FEBS Lett. 589:2791–2796. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ling JW, Lu PR, Zhang YB, Jiang S and Zhang ZC: miR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN. Genet Mol Res. 16:2017. View Article : Google Scholar : PubMed/NCBI | |
|
Peng J, Liu H and Liu C: MiR-155 promotes uveal melanoma cell proliferation and invasion by regulating NDFIP1 expression. Technol Cancer Res Treat. 16:1160–1167. 2017. View Article : Google Scholar | |
|
Wang X, Hu Y, Cui J, Zhou Y and Chen L: Coordinated targeting of MMP-2/MMP-9 by miR-296-3p/FOXCUT exerts tumor-suppressing effects in choroidal malignant melanoma. Mol Cell Biochem. 445:25–33. 2018. View Article : Google Scholar | |
|
Zhou J, Jiang J, Wang S and Xia X: Oncogenic role of microRNA-20a in human uveal melanoma. Mol Med Rep. 14:1560–1566. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yang C and Wei W: The miRNA expression profile of the uveal melanoma. Sci China Life Sci. 54:351–358. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD and Triozzi PL: Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol. 58:182–186. 2014. View Article : Google Scholar : | |
|
Venza I, Visalli M, Beninati C, Benfatto S, Teti D and Venza M: IL-10Rα expression is post-transcriptionally regulated by MIR-15a, MIR-185, and MIR-211 in melanoma. BMC Med Genomics. 8:812015. View Article : Google Scholar | |
|
Sun Q, Cong R, Yan H, Gu H, Zeng Y, Liu N, Chen J and Wang B: Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol Rep. 22:563–567. 2009.PubMed/NCBI | |
|
Tuaeva NO, Falzone L, Porozov YB, Nosyrev AE, Trukhan VM, Kovatsi L, Spandidos DA, Drakoulis N, Kalogeraki A, Mamoulakis C, et al: Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. Cells. 8:12512019. View Article : Google Scholar : | |
|
Falzone L, Musso N, Gattuso G, Bongiorno D, Palermo CI, Scalia G, Libra M and Stefani S: Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection. Int J Mol Med. 46:957–964. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Falzone L, Gattuso G, Lombardo C, Lupo G, Grillo CM, Spandidos DA, Libra M and Salmeri M: Droplet digital PCR for the detection and monitoring of Legionella pneumophila. Int J Mol Med. 46:1777–1782. 2020.PubMed/NCBI | |
|
Salemi R, Falzone L, Madonna G, Polesel J, Cinà D, Mallardo D, Ascierto PA, Libra M and Candido S: MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAFV600E mutation detected in circulating-free DNA. Front Pharmacol. 9:8562018. View Article : Google Scholar |
